School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich, UK.
Br J Pharmacol. 2009 Aug;157(7):1186-8. doi: 10.1111/j.1476-5381.2009.00266.x.
The endogenous protein, tumour necrosis factor receptor apoptosis-inducing ligand (TRAIL), induces apoptosis in a wide variety of transformed and cancer cells but has little or no effect on normal cells. Therefore, TRAIL is considered to be a tumour-selective, apoptosis-inducing cytokine and a promising new candidate for cancer prevention and treatment. Some cancer cells are however resistant to TRAIL-induced apoptosis, but treatment in combination with conventional chemotherapeutic drugs or radiation generally restores TRAIL sensitivity in those cells. A novel class of molecules exhibiting synergy with TRAIL but devoid of major side effects are emerging as alternative approaches to treat resistant cancer cells, including natural antioxidants such as sulphoraphane or the flavonoids curcumin, quercetin, resveratrol, baicalein and wogonin. In this issue of the BJP, Lee et al. demonstrate that treatment of TRAIL-resistant cancer cells with wogonin restores TRAIL-induced cell death in a reactive oxygen species-dependent manner through up-regulation of p53 and Puma.
内源性蛋白肿瘤坏死因子受体凋亡诱导配体(TRAIL)可诱导多种转化和癌细胞凋亡,但对正常细胞几乎没有或没有影响。因此,TRAIL 被认为是一种肿瘤选择性凋亡诱导细胞因子,是癌症预防和治疗的有前途的新候选药物。然而,一些癌细胞对 TRAIL 诱导的凋亡具有抗性,但与常规化疗药物或放射治疗联合治疗通常可恢复这些细胞对 TRAIL 的敏感性。一类具有 TRAIL 协同作用且无主要副作用的新型分子作为治疗耐药癌细胞的替代方法正在出现,包括天然抗氧化剂如萝卜硫素或类黄酮姜黄素、槲皮素、白藜芦醇、白杨素和黄芩素。在 BJP 的本期中,Lee 等人证明,用黄芩素处理 TRAIL 耐药癌细胞可通过上调 p53 和 Puma 以依赖活性氧的方式恢复 TRAIL 诱导的细胞死亡。